# Nath Bio-Genes (India) (NSE: NATHBIOGEN) share price, financials and shareholding Source: https://app.pivotnow.in/stock/NATHBIOGEN · Pivot · prices to 22 Oct 2026 Nath Bio-Genes (India) (NSE: NATHBIOGEN) closed at ₹132.60 on 22 Oct 2026, up 0.76% on the day. With a market capitalisation of ₹252 Cr, it ranks 2138th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Agricultural Inputs. At its last close the stock traded at 6.3× trailing earnings, against a return on equity of 6.1% in FY26. Over the past year the share price has fallen 23.0%. Its 52-week range is ₹126.15 (30 Mar 2026) to ₹204.00 (30 Apr 2026); the last close is 35.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹328 Cr (+15.8% year on year) and net profit ₹32 Cr (−13.5%), on a consolidated basis. Promoters held 45.60% of the company as of 30 Jun 2026; 13.78% of promoter shares were pledged. ## Key numbers | Metric | Value | | --- | --- | | Last close | ₹132.60 | | Market cap | ₹252 Cr | | P/E (trailing) | 6.3 | | ROE | 6.1% (FY26) | | ROCE | 8.0% (FY26) | | Debt to equity | 0.2 | | 52-week high | ₹204.00 (30 Apr 2026) | | 52-week low | ₹126.15 (30 Mar 2026) | | 1-year return | −23.0% | ## Quarterly results (₹ crore, consolidated) | Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) | | --- | --- | --- | --- | --- | --- | | Q1 FY27 | ₹328 Cr | +15.8% | ₹32 Cr | −13.5% | ₹16.98 | | Q4 FY26 | ₹52 Cr | −0.7% | −₹0 Cr | −100.7% | −₹0.79 | | Q3 FY26 | ₹66 Cr | +78.9% | ₹2 Cr | −39.2% | ₹0.84 | | Q2 FY26 | ₹44 Cr | +36.2% | ₹5 Cr | +334.2% | ₹1.40 | | Q1 FY26 | ₹284 Cr | +16.3% | ₹37 Cr | +11.8% | ₹19.58 | | Q4 FY25 | ₹52 Cr | +20.7% | ₹1 Cr | −43.5% | ₹0.42 | | Q3 FY25 | ₹37 Cr | +16.2% | ₹3 Cr | −30.6% | ₹1.33 | | Q2 FY25 | ₹32 Cr | +42.6% | ₹1 Cr | −45.3% | ₹0.53 | ## Annual results (₹ crore) | Fiscal year | Revenue | Net profit | | --- | --- | --- | | FY25 | ₹365 Cr | ₹39 Cr | | FY24 | ₹333 Cr | ₹40 Cr | | FY23 | ₹301 Cr | ₹35 Cr | | FY22 | ₹278 Cr | −₹67 Cr | | FY13 | ₹138 Cr | ₹12 Cr | ## Shareholding (30 Jun 2026) - Promoters: 45.60% - Foreign institutions: 0.27% - Domestic institutions: 0.01% - Non-institutions: 54.13% ## Peers | Company | Price | Market cap | P/E | ROE | | --- | --- | --- | --- | --- | | [Espire Hospital](https://app.pivotnow.in/stock/ESPIRE) | — | ₹274 Cr | — | — | | [Zenotech Labs](https://app.pivotnow.in/stock/ZENOTECH) | — | ₹270 Cr | — | — | | [Everest Organic](https://app.pivotnow.in/stock/EVERESTO) | — | ₹262 Cr | — | — | | [Gennex Labs](https://app.pivotnow.in/stock/GENNEX) | — | ₹254 Cr | — | — | | [Kerala Ayur](https://app.pivotnow.in/stock/KERALAYUR) | — | ₹254 Cr | — | — | | [BDH Industries](https://app.pivotnow.in/stock/BDH) | — | ₹252 Cr | — | — | ## Questions and answers ### What is the share price of Nath Bio-Genes (India) today? Nath Bio-Genes (India) (NSE: NATHBIOGEN) last closed at ₹132.60 on 22 Oct 2026. Its 52-week high is ₹204.00 and its 52-week low is ₹126.15. ### What is the market cap of Nath Bio-Genes (India)? Nath Bio-Genes (India)'s market capitalisation is ₹252 Cr (₹252 Cr) at the 22 Oct 2026 close, ranking 2138th among the NSE companies Pivot tracks. ### What is the P/E ratio of Nath Bio-Genes (India)? Nath Bio-Genes (India) trades at a trailing P/E of 6.3. ### What is the ROE and ROCE of Nath Bio-Genes (India)? Return on equity was 6.1% in FY26 and return on capital employed was 8.0% in FY26 (consolidated figures). ### Is Nath Bio-Genes (India) a debt-free company? No. Nath Bio-Genes (India)'s debt-to-equity ratio was 0.2 in FY26, with total debt of ₹17 Cr. ### What were Nath Bio-Genes (India)'s latest quarterly results? For Q1 FY27 (quarter ended 30 Jun 2026), Nath Bio-Genes (India) reported revenue of ₹328 Cr, +15.8% year on year, and net profit of ₹32 Cr, −13.5% year on year. ### How has Nath Bio-Genes (India) stock performed over the last year? Nath Bio-Genes (India)'s share price has fallen 23.0% over the past year, −18.4% over three months and −13.3% over one month, to the 22 Oct 2026 close. ### What is the shareholding pattern of Nath Bio-Genes (India)? As of 30 Jun 2026: promoters 45.60%, foreign institutions 0.27%, domestic institutions 0.01%, non-institutions 54.13%. 13.78% of promoter shares were pledged. ### Who are Nath Bio-Genes (India)'s competitors? The listed Pharma & Healthcare companies closest to Nath Bio-Genes (India) by market cap are Espire Hospital, Zenotech Labs, Everest Organic, Gennex Labs, Kerala Ayur and BDH Industries. ### Is Nath Bio-Genes (India) a good stock to buy? Pivot does not give buy or sell recommendations. This page sets out Nath Bio-Genes (India)'s price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NATHBIOGEN against its own history before risking money. This is analysis, not financial advice. --- Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.